EGFR and cancer prognosis - PubMed (original) (raw)

Review

EGFR and cancer prognosis

R I Nicholson et al. Eur J Cancer. 2001 Sep.

Abstract

Elevated levels of the epidermal growth factor receptor (EGFR), a growth-factor-receptor tyrosine kinase, and/or its cognate ligands have been identified as a common component of multiple cancer types and appear to promote solid tumour growth. This article examines the relationship between EGFR expression and cancer prognosis based on literature compiled on PubMed between 1985 and September 2000. More than 200 studies were identified that analysed relapse-free-interval or survival data directly in relation to EGFR levels in over 20000 patients. Analysis of the data showed that 10 cancer types both express elevated levels of EGFR relative to normal tissues and have been studied in sufficient depth to allow sound judgements to be made concerning the association between EGFR and patient outlook. The EGFR was found to act as a strong prognostic indicator in head and neck, ovarian, cervical, bladder and oesophageal cancers. In these cancers, increased EGFR expression was associated with reduced recurrence-free or overall survival rates in 70% (52/74) of studies. In gastric, breast, endometrial and colorectal cancers, the EGFR provided more modest prognostic information, correlating to poor survival rates in 52% (13/25) of studies, while in non-small cell lung cancer (NSCLC), EGFR expression only rarely (3/10 studies) related to patient outlook. However, it is likely that the true prognostic significance of the EGFR has been underestimated as the published studies only assessed total cellular EGFR levels, rather than the activated form of the receptor, and were not standardised with regard to patient populations or assay methods. Finally, it is important to stress that failure to detect a prognostic significance for EGFR in any one cancer type does not necessarily preclude patients from benefiting from anti-EGFR therapies.

PubMed Disclaimer

Cited by

Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.
Zhang M, Taylor CE, Piao L, Datta J, Bruno PA, Bhave S, Su T, Lang JC, Xie X, Teknos TN, Mapp AK, Pan Q. Zhang M, et al. Mol Cancer Ther. 2013 Aug;12(8):1515-25. doi: 10.1158/1535-7163.MCT-12-1110. Epub 2013 May 30. Mol Cancer Ther. 2013. PMID: 23723125 Free PMC article.
The route to personalized medicine in bladder cancer: where do we stand?
Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, Montironi R, Santini D, Cheng L, Martignoni G, Cascinu S, Tortora G. Massari F, et al. Target Oncol. 2015 Sep;10(3):325-36. doi: 10.1007/s11523-015-0357-x. Epub 2015 Jan 30. Target Oncol. 2015. PMID: 25634607 Review.
Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways.
Yoshida GJ. Yoshida GJ. J Exp Clin Cancer Res. 2020 Jun 16;39(1):112. doi: 10.1186/s13046-020-01611-0. J Exp Clin Cancer Res. 2020. PMID: 32546182 Free PMC article. Review.
Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
El Guerrab A, Bamdad M, Kwiatkowski F, Bignon YJ, Penault-Llorca F, Aubel C. El Guerrab A, et al. Oncotarget. 2016 Nov 8;7(45):73618-73637. doi: 10.18632/oncotarget.12037. Oncotarget. 2016. PMID: 27655662 Free PMC article.
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F. Luber B, et al. BMC Cancer. 2011 Dec 7;11:509. doi: 10.1186/1471-2407-11-509. BMC Cancer. 2011. PMID: 22152101 Free PMC article. Clinical Trial.

EGFR and cancer prognosis - PubMed (original) (raw)